Proteasome chymotrypsin-like activity in plasma as a useful marker for children with acute lymphoblastic leukemia
- 7 November 2011
- journal article
- research article
- Published by Taylor & Francis in Scandinavian Journal of Clinical and Laboratory Investigation
- Vol. 72 (1) , 67-72
Abstract
Background. The proteasome chymotrypsin-like (Cht-L) activity was determined in plasma of children with acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) in correlation to baseline leukocytosis, immunophenotype, LDH at the time of diagnosis and after remission induction. Procedure. The activity was assayed using the fluorogenic peptide substrate in the presence of an artificial activator sodium dodecyl sulfate (SDS) in the plasma of healthy donors (n=25), acute lymphoblastic leukemia, ALL (n=95) and AML (n=17) patients. Results. As compared to healthy subjects, the plasma proteasome ChT-L activity was significantly increased (p=0.001) in ALL patients prior to treatment, especially in those with T-ALL immunophenotype and with high LDH activity. Similarly, in AML patients the plasma proteasome ChT-L activity was elevated (p=0.001). Following remission-inducing chemotherapy, the activity of the ChT-L proteasome was significantly reduced both in ALL and AML patients. Conclusion. Plasma proteasome ChT-L activity may serve as an additional marker in monitoring anticancer therapy.Keywords
This publication has 30 references indexed in Scilit:
- Proteasome Inhibition and Allogeneic Hematopoietic Stem Cell Transplantation: A ReviewTransplantation and Cellular Therapy, 2009
- Proteasome Enzymatic Activities in Plasma as Risk Stratification of Patients with Acute Myeloid Leukemia and Advanced-Stage Myelodysplastic SyndromeClinical Cancer Research, 2009
- Extracellular, circulating proteasomes and ubiquitin — Incidence and relevanceBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2008
- Enzymatic activity of circulating proteasomes correlates with clinical behavior in patients with chronic lymphocytic leukemiaCancer, 2008
- Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myelomaBlood, 2007
- The proteasome inhibitors bortezomib and PR‐171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukaemia cellsBritish Journal of Haematology, 2007
- Circulating proteasome levels are an independent prognostic factor for survival in multiple myelomaBlood, 2006
- Proteasome inhibitors: antitumor effects and beyondLeukemia, 2006
- The ubiquitin-proteasome system in cardiac physiology and pathologyAmerican Journal of Physiology-Heart and Circulatory Physiology, 2006
- A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye bindingAnalytical Biochemistry, 1976